Tradestie Institutional Equity Comparison Engine

ABVE vs MBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MBIO Overall Edge

MBIO Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Mustang Bio, Inc. (MBIO) driven by superior Growth & Margin, Momentum & Technical while ABVE counters with relative strength in Options & Structure. Fundamentally, ABVE trades at N/M Forward P/E with -23.2% operating margin (-45.0% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABVE sits in UNCLASSIFIED (8th %ile IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABVE N/M vs MBIO N/M Fwd P/E
Growth & Margin Winner MBIO
Op Margin -23.2% vs 0.0% ยท YoY -45.0% vs +0.0%
Momentum & Technical Winner MBIO
1Y -90.2% vs -67.4% ยท 52W Pos 0% vs 4%
Options & Structure Winner ABVE
UNCLASSIFIED (8th %ile IV) vs UNCLASSIFIED (N/A IV)
ABVE NASDAQ
Above Food Ingredients Inc. Common Stock
Food And Kindred Products
$0.11
-80.57% 1D
Market Cap $30.0M
1M Return -79.18%
1Y Return -90.17%
Forward P/E N/M
Unified AI Score
39.8 / 100 SELL
Tech 40.0 Fund 47.0 Flow 57.0 Mom 40.0
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap $3.2M
1M Return +4.86%
1Y Return -67.38%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABVE -90.17% MBIO -67.38% Spread: +57.93 pp (MBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABVE TTM Op. Margin: -23.2% MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVE vs MBIO. Trailing 12-month operating profitability (ABVE -23.2% vs MBIO 0.0%) and valuation multiples (ABVE N/M vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABVE (2) vs MBIO (6)
Institutional Metric ABVE MBIO Criterion Row Winner
Market Capitalization Scale $30.0M $3.2M Larger Scale ABVE
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -45.0% +0.0% Higher Growth MBIO
Operating Margin (TTM) Profitability -23.2% 0.0% Higher Margin MBIO
Net Profit Margin Profitability -23.4% 0.0% Higher Margin MBIO
Return on Equity (ROE) Capital Efficiency 0.0% -43.1% Higher ROE ABVE
52-Week Range Position Momentum 0% ($0โ€“$7) 4% ($0โ€“$1) Stronger Trend MBIO
Beta / 30D Volatility Risk Regime 4.10ฮฒ ยท 310% Vol 0.66ฮฒ ยท 86% Vol Lower Realized Risk MBIO
Unified Institutional Score Composite Signal 39.8 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite MBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABVE vs MBIO Buy Guide
ABVE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ABVE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABVE nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.